These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 25609807)

  • 1. Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
    Delaloye J; Filali-Mouhim A; Cameron MJ; Haddad EK; Harari A; Goulet JP; Gomez CE; Perdiguero B; Esteban M; Pantaleo G; Roger T; Sékaly RP; Calandra T
    J Virol; 2015 Apr; 89(7):3819-32. PubMed ID: 25609807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.
    Gómez CE; Perdiguero B; Nájera JL; Sorzano CO; Jiménez V; González-Sanz R; Esteban M
    J Virol; 2012 May; 86(9):5026-38. PubMed ID: 22419805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.
    Perdiguero B; Gómez CE; Di Pilato M; Sorzano CO; Delaloye J; Roger T; Calandra T; Pantaleo G; Esteban M
    PLoS One; 2013; 8(9):e74831. PubMed ID: 24069354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
    García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
    PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
    Quakkelaar ED; Redeker A; Haddad EK; Harari A; McCaughey SM; Duhen T; Filali-Mouhim A; Goulet JP; Loof NM; Ossendorp F; Perdiguero B; Heinen P; Gomez CE; Kibler KV; Koelle DM; Sékaly RP; Sallusto F; Lanzavecchia A; Pantaleo G; Esteban M; Tartaglia J; Jacobs BL; Melief CJ
    PLoS One; 2011 Feb; 6(2):e16819. PubMed ID: 21347234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.
    Gómez CE; Perdiguero B; Sánchez-Corzo C; Sorzano COS; Esteban M
    Viruses; 2017 Dec; 10(1):. PubMed ID: 29280955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.
    Nájera JL; Gómez CE; García-Arriaza J; Sorzano CO; Esteban M
    PLoS One; 2010 Jun; 5(6):e11406. PubMed ID: 20613977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
    Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
    Front Immunol; 2019; 10():2941. PubMed ID: 31921191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
    Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
    J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
    García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
    PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and utility of innate immune system evasion mechanisms of ASFV.
    Correia S; Ventura S; Parkhouse RM
    Virus Res; 2013 Apr; 173(1):87-100. PubMed ID: 23165138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
    Kibler KV; Asbach B; Perdiguero B; García-Arriaza J; Yates NL; Parks R; Stanfield-Oakley S; Ferrari G; Montefiori DC; Tomaras GD; Roederer M; Foulds KE; Forthal DN; Seaman MS; Self S; Gottardo R; Phogat S; Tartaglia J; Barnett S; Cristillo AD; Weiss D; Galmin L; Ding S; Heeney JL; Esteban M; Wagner R; Pantaleo G; Jacobs BL
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.
    Di Pilato M; Mejías-Pérez E; Sorzano COS; Esteban M
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28424281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.